Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
bioAffinity Technologies Inc. Warrant (BIAFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BIAFW (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 32.75% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 28357 | Beta 3.14 | 52 Weeks Range 0.12 - 2.90 | Updated Date 02/25/2025 |
52 Weeks Range 0.12 - 2.90 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -90.16% | Operating Margin (TTM) -83.98% |
Management Effectiveness
Return on Assets (TTM) -62.34% | Return on Equity (TTM) -167% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 10680306 |
Shares Outstanding - | Shares Floating 10680306 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
bioAffinity Technologies Inc. Warrant
Company Overview
History and Background
bioAffinity Technologies, Inc. is a clinical-stage cancer diagnostics company. The company was founded to address the need for early cancer detection using non-invasive tests.
Core Business Areas
- CyPathu00ae Lung: A flow cytometry-based test for early lung cancer detection from sputum samples.
Leadership and Structure
bioAffinity Technologies is led by a management team and a board of directors. Details on specific individuals and the detailed organizational structure are publicly available on their investor relations website.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: A test for early lung cancer detection. Market share data specific to bioAffinity is difficult to ascertain due to the competitive landscape. Competitors include companies that offer lung cancer screening tools such as low-dose CT scans (LDCT) offered by various healthcare providers, and companies developing liquid biopsy technologies for lung cancer detection such as Guardant Health (GH).
Market Dynamics
Industry Overview
The cancer diagnostics industry is characterized by innovation and competition. There's a growing focus on early detection and personalized medicine.
Positioning
bioAffinity Technologies aims to differentiate itself through its non-invasive sputum-based diagnostic technology. They are targeting individuals at high risk for lung cancer.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is substantial, encompassing the global population at risk for the disease. bioAffinity is positioned to capture a segment of this market with its CyPathu00ae Lung test.
Upturn SWOT Analysis
Strengths
- Non-invasive testing method
- Potential for early lung cancer detection
- Proprietary technology
Weaknesses
- Limited market penetration currently
- Requires further validation through clinical trials
- Dependence on a single primary product
Opportunities
- Expanding market for early cancer diagnostics
- Partnerships with healthcare providers and payers
- Potential for expanding the CyPath platform to other cancers
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- GH
Competitive Landscape
bioAffinity faces strong competition from established companies in the diagnostics and screening space. Its non-invasive approach is a key differentiator.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on commercialization and clinical trial performance.
Future Projections: Future growth depends on clinical trial outcomes and ability to gain regulatory and payer approvals.
Recent Initiatives: Recent initiatives include clinical trials and commercialization plans for CyPathu00ae Lung.
Summary
bioAffinity Technologies is a clinical-stage company with a promising non-invasive lung cancer diagnostic test. Its success hinges on successful clinical trial results, regulatory approvals, and commercial adoption. The company faces significant competition and requires substantial funding to achieve its goals. They will need to focus on partnerships and funding to build out this diagnostic test.
Similar Companies
- GH
Sources and Disclaimers
Data Sources:
- bioAffinity Technologies' investor relations website
- Publicly available information and press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data and analysis are based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies Inc. Warrant
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 75 | Website https://www.bioaffinitytech.com |
Full time employees 75 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.